Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
$0.00
$0.00
$0.00
▼
$0.00
N/AN/A8,820 shsN/A
CATV
4Cable TV International
$0.00
$0.00
▼
$0.00
N/AN/A3.79 million shs19.50 million shs
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
$0.00
$0.00
▼
$0.07
N/AN/A1.28 million shsN/A
1933 Industries Inc. stock logo
TGIFF
1933 Industries
$0.01
+13.3%
$0.01
$0.00
▼
$0.02
N/AN/A61,062 shs20,250 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
0.00%0.00%0.00%+1.00%+1.00%
CATV
4Cable TV International
0.00%0.00%0.00%0.00%-66.67%
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00%0.00%0.00%0.00%0.00%
1933 Industries Inc. stock logo
TGIFF
1933 Industries
-7.69%-11.76%+5.26%+30.43%-49.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
$0.00
$0.00
$0.00
▼
$0.00
N/AN/A8,820 shsN/A
CATV
4Cable TV International
$0.00
$0.00
▼
$0.00
N/AN/A3.79 million shs19.50 million shs
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
$0.00
$0.00
▼
$0.07
N/AN/A1.28 million shsN/A
1933 Industries Inc. stock logo
TGIFF
1933 Industries
$0.01
+13.3%
$0.01
$0.00
▼
$0.02
N/AN/A61,062 shs20,250 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
0.00%0.00%0.00%+1.00%+1.00%
CATV
4Cable TV International
0.00%0.00%0.00%0.00%-66.67%
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00%0.00%0.00%0.00%0.00%
1933 Industries Inc. stock logo
TGIFF
1933 Industries
-7.69%-11.76%+5.26%+30.43%-49.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
0.00
N/AN/AN/A
CATV
4Cable TV International
0.00
N/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00
N/AN/AN/A
1933 Industries Inc. stock logo
TGIFF
1933 Industries
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
N/AN/AN/AN/AN/AN/A
CATV
4Cable TV International
N/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/A
1933 Industries Inc. stock logo
TGIFF
1933 Industries
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
N/A-$0.23N/AN/AN/AN/AN/AN/AN/A
CATV
4Cable TV International
N/A-$0.01N/AN/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/AN/AN/AN/A
1933 Industries Inc. stock logo
TGIFF
1933 Industries
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
N/AN/AN/AN/AN/A
CATV
4Cable TV International
N/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/A
1933 Industries Inc. stock logo
TGIFF
1933 Industries
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
34.27%
CATV
4Cable TV International
N/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/A
1933 Industries Inc. stock logo
TGIFF
1933 Industries
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Arno Therapeutics, Inc. stock logo
ARNI
Arno Therapeutics
4N/AN/ANot Optionable
CATV
4Cable TV International
14N/AN/ANot Optionable
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
460N/AN/ANot Optionable
1933 Industries Inc. stock logo
TGIFF
1933 Industries
85N/AN/ANot Optionable

Recent News About These Companies

1933 Industries Inc
1933 Industries Provides Update on 2024 Debenture Conversions
Arno Therapeutics stock logo

Arno Therapeutics OTCMKTS:ARNI

$0.0001 0.00 (0.00%)
As of 10/15/2026

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. was founded in 2005 and is based in Flemington, New Jersey.

4Cable TV International OTCMKTS:CATV

4Cable TV International, Inc. provides specialty solutions to the cable television sector. It offers a suite of products comprising RF to Fiber (RF2F), a proprietary line of coax-to-fiber taps that enables cable operators to reach homes within their franchise authorized area; PowerMiser, a circuitry, which allows a low current 1 GHz amplifier and/or line extender to be constructed with a decrease in current power requirements; RF over Glass (RFoG) signal distribution technology that combines the existing cable TV infrastructure with fiber optics to reach the home; and Node+0 application, which combines the RFoG technology platform with its PowerMiser engineering to take fiber signal. The company also provides SOLAR-CATV that utilizes solar power and helps the operator extend service to areas not presently served without adding power sources; and Dynamically Scalable Return technology, which allows nodes, R-ONU's (RFoG optical network units) to adjust their return bandwidth by changing the channel lineup at the head end, as well as repair, testing, and upgrade services. It markets and sells its products through a network of dealers in the United States and Canada primarily to independent cable TV operators, as well as to multiple system operators. 4Cable TV International, Inc. was incorporated in 2007 and is based in Conway, South Carolina.

4Front Ventures stock logo

4Front Ventures OTCMKTS:FFNTF

4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.

1933 Industries stock logo

1933 Industries OTCMKTS:TGIFF

$0.0068 +0.00 (+13.33%)
As of 04:08 PM Eastern

1933 Industries Inc., together with its subsidiaries, engages in the cultivation and production of cannabis products in the United States. It operates in three segments: the Medical Segment, the Recreational Segment, and the CBD-Infused Products Segment. The company produces, packages, and markets cannabidiol (CBD)-infused products, including tinctures, vape pens and cartridges, lotions, pain creams, gummies, and capsules under the Canna Hemp and Canna Hemp X brand names. It also offers craft-style cannabis, infused pre-rolls, full spectrum oils, distillates, terpenes, and vaporizer products; and boutique concentrates, such as shatters, crumbles, batters, sugar waxes, diamonds, and cured and live resins under the AMA and Level X brand names. The company offers its products through retail dispensaries and retail outlets, as well as through its e-commerce platform. The company was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018. 1933 Industries Inc. is headquartered in Vancouver, Canada.